FLT3 and acute myeloid leukemia: Using NGS to assess the AML driver mutation FLT3-ITD, Jeffrey Miller’s group [38] used BM samples from 15 patients in complete remission (CR), with negative detection of FLT-ITD fragments by capillary electrophoresis and no leukemia-associated phenotype identified by 6-color MCF.